NCT06245018View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2030

Conditions
Solid Tumor
Interventions
BIOLOGICAL

iNK Injection

Subjects will receive about 4 cycles of iNK

Sponsors
All Listed Sponsors
lead

Nuwacell Biotechnologies Co., Ltd.

INDUSTRY